{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:57Z","timestamp":1786998477337,"version":"build-2736575974"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LR20H160003"],"award-info":[{"award-number":["LR20H160003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0909900"],"award-info":[{"award-number":["2021YFA0909900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023ZD0501300"],"award-info":[{"award-number":["2023ZD0501300"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82161138028"],"award-info":[{"award-number":["82161138028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971324"],"award-info":[{"award-number":["31971324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ymthe.2025.02.028","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:21:37Z","timestamp":1740021697000},"page":"1368-1379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Turning \u201ctrashed\u201d genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells"],"prefix":"10.1016","volume":"33","author":[{"given":"Yajie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-0560","authenticated-orcid":false,"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.02.028_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T\u00a0cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.028_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T\u00a0cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.028_bib4","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.02.028_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib7","first-page":"166","article-title":"FDA approves fourth CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.02.028_bib8","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.02.028_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-136038","article-title":"Clinical response of cd19 car-t cells (relmacabtagene autoleucel, relma-cel) in adults with heavily-pre-treated relapsed\/refractory (r\/r) large b-cell lymphoma in China","volume":"136","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib11","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib12","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood-2022-165002","article-title":"Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia (R\/R B-Cell ALL) in China","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2023-173427","article-title":"Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib16","doi-asserted-by":"crossref","first-page":"e15080","DOI":"10.1200\/JCO.2024.42.16_suppl.e15080","article-title":"Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review","volume":"42","author":"Wesson","year":"2024","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib17","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2024-207197","article-title":"Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial","volume":"144","author":"Yin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1182\/blood-2024-210226","article-title":"A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA\/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease","volume":"144","author":"Qiu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib20","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18. 2-specific CAR T\u00a0cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib22","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1182\/blood-2022-170712","article-title":"Off-the-Shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib23","doi-asserted-by":"crossref","first-page":"4846.1","DOI":"10.1182\/blood-2024-212347","article-title":"A Phase 1 Study of NKX019, an Allogeneic Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy in Patients with Systemic Lupus Erythematosus","volume":"144","author":"Askanase","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T\u00a0cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.02.028_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib26","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T\u00a0cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.02.028_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41551-023-01058-6","article-title":"AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells","volume":"8","author":"Ye","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.02.028_bib28","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/ijc.31147","article-title":"Chimeric antigen receptor transduced T\u00a0cells: Tuning up for the next generation","volume":"142","author":"Schubert","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.028_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib30","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T\u00a0cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib32","series-title":"Ninth International Immunology Congress","first-page":"34","article-title":"Efficient retroviral-mediated gene transfer\u00a0into murine primary lymphocytes","author":"Sadelain","year":"1992"},{"key":"10.1016\/j.ymthe.2025.02.028_bib33","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1089\/hum.2005.16.1241","article-title":"Silencing and variegation of gammaretrovirus and lentivirus vectors","volume":"16","author":"Ellis","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib34","first-page":"1107","article-title":"Hematopoietic stem cell engineering at a crossroads","volume":"119","author":"Rivi\u00e8re","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2014.2525","article-title":"Vector integration and tumorigenesis","volume":"25","author":"Von Kalle","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.028_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2017.098","article-title":"Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice","volume":"29","author":"G\u00e1ndara","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2025.02.028_bib39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41563-020-0615-x","article-title":"Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties","volume":"19","author":"Panciera","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ymthe.2025.02.028_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.028_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-step generation of modular CAR-T cells with AAV\u2013Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2025.02.028_bib43","doi-asserted-by":"crossref","first-page":"307ra156","DOI":"10.1126\/scitranslmed.aac5530","article-title":"Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template","volume":"7","author":"Sather","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202100071","article-title":"Cas9-Cleavage sequences in size-reduced plasmids enhance nonviral genome targeting of CARs in primary human T\u00a0cells","volume":"5","author":"Jing","year":"2021","journal-title":"Small Methods"},{"key":"10.1016\/j.ymthe.2025.02.028_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1006\/mthe.2000.0190","article-title":"Lentiviral vectors for enhanced gene expression in human hematopoietic cells","volume":"2","author":"Ramezani","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1089\/hum.2007.067","article-title":"Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential","volume":"18","author":"Weber","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3157","article-title":"AAVS1 site-specific integration of the CAR gene into human primary T\u00a0cells using a linear closed-ended AAV-based DNA vector","volume":"22","author":"Chen","year":"2020","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s13287-021-02648-4","article-title":"Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells","volume":"12","author":"Tang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib49","first-page":"2698","article-title":"Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering","volume":"141","author":"Odak","year":"2023","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib50","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T\u00a0cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib51","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.028_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-023-01799-7","article-title":"Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing","volume":"22","author":"Balke-Want","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.028_bib53","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.02.028_bib54","article-title":"Integration of \u03b6-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood J. Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib55","article-title":"CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib56","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/v15010202","article-title":"Development of HIV-resistant CAR T\u00a0cells by CRISPR\/cas-mediated CAR integration into the CCR5 locus","volume":"15","author":"Rothemejer","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.02.028_bib57","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","article-title":"Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.02.028_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207394","article-title":"CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells","volume":"10","author":"Liao","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2025.02.028_bib59","article-title":"High-affinity CD16 integration into a CRISPR\/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells","volume":"10","author":"Clara","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.028_bib60","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T\u00a0cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T\u00a0cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.028_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymthe.2022.08.018","article-title":"Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib63","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s42003-023-04978-w","article-title":"Activation-inducible CAR expression enables precise control over engineered CAR T\u00a0cell function","volume":"6","author":"Fraessle","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/emmm.201000108","article-title":"Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell","volume":"3","author":"Biasco","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib65","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cts.12466","article-title":"Gene therapy 2017: progress and future directions","volume":"10","author":"Keeler","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymthe.2025.02.028_bib66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.1717","article-title":"Genomic safe harbors permit high \u03b2-globin transgene expression in thalassemia induced pluripotent stem cells","volume":"29","author":"Papapetrou","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc3179","article-title":"Safe harbours for the integration of new DNA in the human genome","volume":"12","author":"Sadelain","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.028_bib68","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1002\/j.1460-2075.1992.tb05614.x","article-title":"Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination","volume":"11","author":"Kotin","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.02.028_bib69","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1101\/gr.106773.110","article-title":"Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome","volume":"20","author":"DeKelver","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib70","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/mt.2016.38","article-title":"Gene insertion into genomic safe harbors for human gene therapy","volume":"24","author":"Papapetrou","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib71","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1634\/stemcells.2007-0039","article-title":"Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration","volume":"26","author":"Smith","year":"2008","journal-title":"Stem cells"},{"key":"10.1016\/j.ymthe.2025.02.028_bib72","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature06894","article-title":"Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population","volume":"453","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.028_bib73","first-page":"5561","article-title":"Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease\u2013mediated safe harbor targeting","volume":"117","author":"Zou","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib74","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1093\/nar\/gkr409","article-title":"Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors","volume":"39","author":"Ramachandra","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib75","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nbt1362","article-title":"Identification and targeting of the ROSA26 locus in human embryonic stem cells","volume":"25","author":"Irion","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116032","article-title":"Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines","volume":"10","author":"Cerbini","year":"2015","journal-title":"PLoS one"},{"key":"10.1016\/j.ymthe.2025.02.028_bib77","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1182\/blood-2021-153258","article-title":"A bicistronic vector expressing CD16 and a membrane bound IL-15 construct in iPSC derived NK cells increased cytotoxicity and persistence","volume":"138","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib78","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.02.028_bib79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41421-023-00552-0","article-title":"High-efficiency targeted transgene integration via primed micro-homologues","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.ymthe.2025.02.028_bib80","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1093\/nar\/gkw064","article-title":"Knock-in of large reporter genes in human cells via CRISPR\/Cas9-induced homology-dependent and independent DNA repair","volume":"44","author":"He","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib81","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41551-023-01037-x","article-title":"Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus","volume":"7","author":"Chavez","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.02.028_bib82","doi-asserted-by":"crossref","first-page":"10590","DOI":"10.1093\/nar\/gkaa779","article-title":"Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain","volume":"48","author":"Ma","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib83","first-page":"612","article-title":"Research briefing","volume":"7","author":"Chavez","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.028_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109625","article-title":"PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges","volume":"121","author":"McGowan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.02.028_bib85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019allogeneic CAR T\u00a0cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.02.028_bib86","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T\u00a0cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib87","first-page":"1","article-title":"Targeting T\u00a0cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib88","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2025.02.028_bib89","doi-asserted-by":"crossref","first-page":"110693","DOI":"10.18632\/oncotarget.22690","article-title":"Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.02.028_bib90","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib91","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Valsecchi","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib92","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1182\/blood-2022-168128","article-title":"A first-in-Human phase 1, multicenter, open-label study of CB-010, a next-generation CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with Relapsed\/Refractory b cell non-Hodgkin lymphoma (ANTLER study)","volume":"140","author":"O'Brien","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib93","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T\u00a0cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.02.028_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz448","article-title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib95","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T\u00a0cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib96","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T\u00a0cells in trials: recent achievements and challenges that remain in the production of modified T\u00a0cells for clinical applications","volume":"29","author":"K\u00f6hl","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.02.028_bib97","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41591-021-01340-7","article-title":"Context matters in CAR T\u00a0cell tonic signaling","volume":"27","author":"Hege","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib98","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib99","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T\u00a0cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI insight"},{"key":"10.1016\/j.ymthe.2025.02.028_bib100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/2326-6066.CIR-20-0451","article-title":"Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling","volume":"9","author":"Landoni","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib101","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T\u00a0cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib102","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2025.02.028_bib103","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T\u00a0cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.028_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00277","article-title":"Maraviroc\u2013a CCR5 antagonist for the treatment of HIV-1 infection","volume":"6","author":"Van Der Ryst","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cellule"},{"key":"10.1016\/j.ymthe.2025.02.028_bib106","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nbt1410","article-title":"Establishment of HIV-1 resistance in CD4+ T\u00a0cells by genome editing using zinc-finger nucleases","volume":"26","author":"Perez","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib107","first-page":"285","article-title":"CD7-edited T\u00a0cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib108","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T\u00a0cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2025.02.028_bib109","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T\u00a0cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.02.028_bib110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.02.028_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232915","article-title":"Promoter choice: Who should drive the CAR in T\u00a0cells?","volume":"15","author":"Rad S M","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.02.028_bib112","first-page":"63","article-title":"Promoter\u2019s choice drive CAR-T efficiency","volume":"04","author":"Anna","year":"2021","journal-title":"J.\u00a0Biotechnol. Biomed."},{"key":"10.1016\/j.ymthe.2025.02.028_bib113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41590-023-01696-7","article-title":"CAR macrophages on a fast track to solid tumor therapy","volume":"25","author":"Abdin","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.028_bib115","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2021-148687","article-title":"Development of chimeric antigen receptor-expressing ipsc-derived macrophages with improved anti-tumor activity","volume":"138","author":"Pouyanfard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib116","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1182\/blood-2022-159752","article-title":"Targeted Genomic Insertion of Cars in iPSC-Derived Macrophages Leads to Improved Expression and Anti-Tumor Activity","volume":"140","author":"Kong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.028_bib117","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2025.02.028_bib118","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.02.028_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9209","article-title":"Engineering light-controllable CAR T\u00a0cells for cancer immunotherapy","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.02.028_bib120","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","article-title":"Enhanced intratumoural activity of CAR T\u00a0cells engineered to produce immunomodulators under photothermal control","volume":"5","author":"Miller","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2025.02.028_bib121","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","article-title":"Control of the activity of CAR-T cells within tumours via focused ultrasound","volume":"5","author":"Wu","year":"2021","journal-title":"Nat. Biomed. Eng."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:05:58Z","timestamp":1775102758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1525001625001182"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.028","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Turning \u201ctrashed\u201d genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}